Endosense, a leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has launched the TactiCath 75 force-sensing ablation catheter in Europe.

The TactiCath 75 is an 8.5 F sheath compatible, state-of-the-art open irrigated, steerable radiofrequency ablation catheter that utilises the same proprietary force-sensing technology as the original TactiCath in the catheter ablation treatment of atrial fibrillation (AF).

Endosense’s distribution partner, Biotronik markets TactiCath 75 in Europe, and is expected to be available soon for use in the Toccastar US investigational device exemption (IDE) study of the TactiCath.

The company also announced the results of the Efficas clinical study of contact force-sensing in catheter ablation procedures.

The 46-patient single-arm prospective multi-center Efficas trial is intended to evaluate the correlation between contact forces applied during pulmonary vein isolation (PVI), gap formation at three months, and atrial fibrillation (AF) treatment efficacy.

The study results showed that the formation of a continuous line of ablation points performed with a minimum force of 10 grams and a minimum Force-Time Integral (FTI) of 400 gram seconds provides higher success rate in electrical isolation per pulmonary vein segment.

Endosense president and CEO Jan Keltjens said the findings from Efficas continue to demonstrate the clear value of contact-force sensing in catheter ablation procedures, as they prove that electrical reconnections caused by inadequate, non-transmural lesions can be avoided with the use force and FTI information.